The clearance allows human trials for its one-time treatment targeting a genetic eye disease that causes vision loss.

The firm plans to enroll US patients into the trial of GEB-101 in the second quarter, having launched an investigator-initiated trial in China.

The US Food and Drug Administration (FDA) has cleared GenEditBio Limited’s Investigational New Drug (IND) application to ...

GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S.

The cornea is crucial for focusing light onto the retina. When injuries or diseases damage its ability to regenerate new cells, vision can be severely compromised. The new treatment is called ...

A Scots pensioner who "spent half his life in the dark" will be able to see Christmas properly for the first time in years after receiving a life-changing cornea transplant. David Watkins, 72, from ...